1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

GSK Airs Phase III Data For Weekly GLP-1 Albiglutide, Plans To File By Year-End

 
• By Emily Hayes

GSK/Human Genome Sciences’ once-weekly injectable GLP-1 agonist albiglutide succeeds in a non-inferiority study and should be filed in late 2012. But analysts critique efficacy relative to the competition and some say the diabetes drug will come to the market too late.

With the release of top-line data from the successful Phase III Harmony 6 trial of once-weekly albiglutide – a member of the increasingly popular but competitive class of GLP-1 agonists – GlaxoSmithKline Inc.noted it has the pivotal trials in hand to support a regulatory filing in type 2 diabetes by the end of 2012.

A subcutaneous injectable, albiglutide was developed by Human Genome Sciences Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D